Therefore, investigating the downstream mechanisms of AMPK regulation in hepatic lipid metabolism can provide theoretical basis for MASLD treatment through targeted AMPK activation, but may not explain the pathogenesis of MASLD. The gene discussed is PRKAA1; the disease is metabolic dysfunction-associated steatotic liver disease.